Myeloproliferative Neoplasms

Justin T Ertle, MD and James Evan Davidson, MD Reviewed 05/2023

BASICS

DESCRIPTION

Myeloproliferative neoplasms (MPNs) are a group of clonal disorders that all originate in the pluripotent hematopoietic stem cell. This topic focuses on chronic myelogenous leukemia ...

DIAGNOSIS

HISTORY

Constitutional symptoms are common, though a significant minority are asymptomatic.

Any MPN may have these symptoms (1):
- Constitutional: fatigue, weakness, night sweats,...

TREATMENT

Strategy is based on risk assessment and symptom burden; validated risk models are available for each MPN. (1)

GENERAL MEASURES

PV:
- Phlebotomy is first line; goal hematocrit <4...

ONGOING CARE

PATIENT EDUCATION

Avoid situations increasing risk of thrombosis.
With splenomegaly, patients are advised to avoid activities increasing risk of rupture.

PROGNOSIS

CML prognosis is strongly t...

REFERENCES

Patel AB, et al. New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape. Clin Cancer Res. 2016;22(5):1037-47.

ADDITIONAL READING

CODES

ICD10

D47.1 Chronic myeloproliferative disease
C92.10 Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission
D45 Polycythemia vera
D47.3 Essential (hemorrhagic) thrombocythemia
C93...

CLINICAL PEARLS

MPNs result from mutations that activate hematopoiesis, resulting in proliferation of cells of myeloid, erythroid, and/or megakaryocyte lineages.
CML is characterized by granulocytosis,...

Subscribe to Access Full Content

START 10-DAY FREE TRIAL

Subscribe Now

Forgot password?

Enter an Access Code

GET CME/CE